Send to

Choose Destination
Arthritis Res Ther. 2019 Dec 12;21(1):281. doi: 10.1186/s13075-019-2046-0.

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.

Author information

Division of Immunology and Rheumatology, Stanford University, 1000 Welch Rd, #203, Palo Alto, CA, USA.
Coephycient Pharmaceutical Consultancy, Guildford, UK.
Desert Medical Advances, Palm Desert, CA, USA.
Centrum Badań Klinicznych S.C, Poznański Ośrodek Medyczny NOVAMED, Poznań, Poland.
Clínica Internacional, Lima, Peru.
MEDICAL PLUS s.r.o., Uherské Hradiště, Czech Republic; Faculty of Pharmacy, Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
Quantum Research, Puerto Varas, Chile.
National Pirogov Memorial Medical University, Vinnytsia, Ukraine.
Center for Rheumatology and Gastroenterology, Munich, Germany.
First Saint-Petersburg State Medical University, St. Petersburg, Russia.
Fujifilm Kyowa Kirin Biologics, Tokyo, Japan.
Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany.



To compare the efficacy, serum drug concentrations, immunogenicity, and safety of FKB327 with the adalimumab reference product (RP) in combination with methotrexate in patients with moderate-to-severe, active rheumatoid arthritis (RA).


Patients were randomized 1:1 in a double-blind study (NCT02260791), received 40 mg of FKB327 or RP by subcutaneous injection every other week for 24 weeks (Period I), then re-randomized 2:1, remaining on the same study drug or switching to the other up to week 54 in an open-label extension (Period II, NCT02405780). Efficacy was evaluated using American College of Rheumatology (ACR20) response rate difference at week 24 with equivalence margins of ± 13% and - 12% to + 15% using 95% and 90% confidence intervals (CIs), respectively. Efficacy, serum drug concentrations, immunogenicity, and safety were compared at week 54.


A total of 730 patients were randomized in Period I (n = 367 FKB327, n = 363 RP), and 645 transitioned to Period II (n = 216 FKB327-FKB327, n = 108 FKB327-RP, n = 108 RP-FKB327, n = 213 RP-RP). At week 24, ACR20 response rates were 74.1% with FKB327 versus 75.7% with RP. 95% and 90% CI of the response rate difference were - 7.9 to 4.7% and - 7.3 to 3.6%, respectively, meeting predefined equivalence margins. The ACR20 response rate remained over 70% of patients to week 54 with all treatment sequences. In Period I, mean trough serum drug concentrations were slightly higher for patients receiving FKB327 than those receiving RP. Mean concentrations were stable over time and reflected steady state in Period II. The proportions of patients with samples positive for neutralizing antidrug antibodies (ADAs) were comparable (57.7% with FKB327 vs. 55.5% with RP) at week 24, and no consistent difference in ADA were seen between continuous and switched treatments in Period II. Efficacy was slightly reduced in the small proportion of patients with high ADA titers in all treatment groups. No clinically significant differences were observed in the incidence of commonly reported treatment-emergent adverse events between the treatments across Periods I and II.


FKB327 was equivalent to RP in clinical efficacy and demonstrated comparable safety and immunogenicity in patients with moderate-to-severe RA. No effect of switching between FKB327 and RP was observed.

TRIAL REGISTRATION:, NCT02260791, Registered 29 July 2014., NCT02405780, Registered 17 July 2015.


Adalimumab; Biosimilar; Comparative clinical trials; Efficacy; FKB327; Immunogenicity; Pharmacokinetics; Rheumatoid arthritis; Safety

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center